Tag Archives: biotechnology law

Fifty Ways To Leave Your Lover And Nine Ways To Attack Patents

As a “quick guide” to the Patent Reform Bill, H.R. 1249, that will soon become law, these are the sections of the Act and of the present statute that will all be, or remain effective, upon enactment, to facilitate blocking … Continue reading

Posted in Patent Reform Legislation | Tagged , , , , , , , , , , , | Leave a comment

Classen Immunotherapeutics v. Biogen Idec: Corrected Opinion Likely?

On August 31, 2011, a three-judge panel of the Fed. Cir. (Rader, Newman, Moore) revisited the court’s 2009 summary affirmance that the claims of three Classen patents were not directed to patentable subject matter. (A copy is at the end … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 3 Comments

Obviousness Objections Based On Combinations Of References – Consistent Warnings From The CAFC

By Paul Cole, Professor of Intellectual Property Law, Bournemouth University; Lucas & Co, Warlingham, UK Those prosecuting patent applications before the USPTO, the EPO and other examining patent offices confront on a daily basis objections of the kind: “A is known … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , , , , , , | Leave a comment

Cybersource Corp. v. Retail Decisions, Inc.

  In recent posts, I have worried, then warned, the Fed. Cir. holding that the Myriad “analyzing” or “comparing” diagnostic claims were invalid as abstract ideas, would cloud the IP future of “modern” claims to personalized medicine (see posts of … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment